What is chronic lymphocytic leukemia?
CLL develops when a clone of lymphocytes, usually B cells, accumulates in blood and marrow and may enlarge lymph nodes, liver, or spleen. Small lymphocytic lymphoma is the closely related tissue-based form of the same disease spectrum. CLL often follows an indolent course, but its pace varies widely. It is uncommon in children and occurs mainly in older adults. Many people have no symptoms at diagnosis; an elevated lymphocyte count prompts evaluation. Disease biology matters: deletion 17p or TP53 disruption and the mutation status of IGHV can influence risk and treatment selection. CLL can impair normal blood production and immune function and occasionally transform into a faster-growing lymphoma, called Richter transformation. Care depends on stage, symptoms, rate of progression, blood counts, lymph node and spleen findings, molecular biomarkers, previous response, age, other health conditions, and patient preferences. A diagnosis alone does not always mean immediate treatment is beneficial.
Signs and symptoms
CLL may cause no symptoms for years. When symptoms occur, they can include persistent fatigue, painless enlarged lymph nodes in the neck, underarm, abdomen, or groin, and fullness or discomfort under the ribs from an enlarged spleen. Fever without a clear infection, drenching night sweats, or unintentional weight loss may signal active disease. Reduced healthy blood cells can cause shortness of breath or pallor from anemia, easy bruising or bleeding from low platelets, and recurrent or unusually severe infections from immune dysfunction. Rapidly enlarging nodes, new pain, or marked systemic symptoms can raise concern for transformation and need prompt evaluation. None of these features is specific to CLL; infections, autoimmune disease, medicines, and other noncancer conditions can cause similar changes. Trends in symptoms, examination, and blood counts are more informative than any single finding.
Diagnosis and staging
A complete blood count and differential identifies persistent lymphocytosis and possible anemia or low platelets. Peripheral blood flow cytometry detects the characteristic clonal B-cell immunophenotype and often establishes the diagnosis without a marrow biopsy. A blood smear, chemistry studies, and physical examination assess disease effects. Fluorescence in situ hybridization and molecular tests evaluate changes such as deletion 17p, TP53 alteration, and IGHV mutation status; these can guide therapy and may be repeated before a new treatment. Bone marrow examination, CT imaging, or lymph node biopsy is used selectively, including when blood findings are unclear or transformation is suspected. CLL is commonly staged with the Rai or Binet system using lymph node or organ enlargement, anemia, and platelet counts. It is also described as asymptomatic, symptomatic or progressive, recurrent, or refractory. Treatment decisions depend more on active-disease criteria, progression, biomarkers, prior therapy, age, and overall health than on stage alone.
Established treatment paths
People with early, asymptomatic CLL are commonly managed with active observation, including scheduled examinations and blood counts; starting therapy before standard indications appear has not generally improved outcomes. Treatment is considered for progressive marrow failure, bulky or worsening lymph nodes or spleen, rapid lymphocyte increase, troublesome constitutional symptoms, or other active-disease features. Modern first-line options often use targeted therapy, such as a Bruton tyrosine kinase inhibitor or a time-limited venetoclax-based combination with an anti-CD20 antibody. The choice and duration depend on TP53 or deletion 17p status, IGHV status, heart and kidney health, bleeding risk, drug interactions, and preferences about continuous versus fixed-duration therapy. Chemotherapy-based combinations now have a narrower role. Relapsed disease may be treated with a different targeted class, selected antibody-based therapy, cellular therapy, transplant in uncommon high-risk situations, or a clinical trial. Local radiation can sometimes relieve symptoms from an enlarged node or spleen. Care depends on disease status, biomarkers, prior treatment and response, age, comorbidities, and goals. Blood counts, symptoms, and adverse effects guide whether treatment continues, pauses, or changes over time.
Supportive care
CLL can weaken immune defenses even before treatment. Supportive care includes prompt evaluation of infections, vaccination planning with the oncology team, and selective preventive antimicrobials or immunoglobulin replacement when clinically indicated. Clinicians manage fatigue, anemia, bleeding, pain, sleep problems, and treatment-specific effects, and may screen for autoimmune destruction of red cells or platelets. Skin protection and routine age-appropriate cancer screening matter because some second cancers occur more often in CLL. Palliative care can support symptom control and quality of life at any stage. Follow-up tracks blood counts, symptoms, node or spleen changes, and treatment response.
Questions to ask your cancer care team
Use the questions that fit your situation, and add the details that matter most to you.
- Do I currently meet accepted criteria for treatment?
- What do TP53, deletion 17p, and IGHV results mean for my options?
- How will observation or treatment response be monitored?
- Which infections, vaccines, bleeding risks, or drug interactions should I discuss?
- What options would be considered if CLL progresses or transforms?
Clinics for people exploring chronic lymphocytic leukemia care

Sunridge Medical Center
Sunridge Medical reports treating all advanced cancers. Its published materials specifically name chronic lymphocytic leukemia care.
Featured placement is separate from an independent ranking or evidence that a clinic is the best fit for a particular patient.Other source-matched clinic profiles
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.




Sources
Source information checked: 2026-09-29. The links below identify the public and clinic-provided materials used for this page.
- NCI: Chronic Lymphocytic Leukemia Treatment ↗Checked 2026-09-29
- NCI: CLL Treatment—Health Professional Version ↗Checked 2026-09-29
How Cancer Clinic Finder compiles information · Suggest a factual correction